glp-1 agonist in esrd and the kidney: from physiology to pharmacology and outcomes diabetes GLP-1 RECEPTORS AGONISTS Comparisons among

G., Gratzl, S., et al

Mol Med Rep (2012) 5(3):72933

Looking Ahead: Are you Strategically Positioned

Mollan S, Hemmings K, Herd CP, Denton A, Williamson S, Sinclair AJ

The move also ties in with efforts by the broader pharma industry to move away from the unpopular system of high list prices for medicines that are then subject to opaque rebates and reductions by supply chain middlemen like pharmacy benefit managers

Disclaimer : The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition